alla vasylenko / Shutterstock.com
Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board (PTAB), effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
PTAB, Alkermes, life sciences, Andrei Iancu, USPTO, US District Court for the District of Delaware, inter partes, drug patents, biologics, petitions